Black Diamond Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-T. Rowe Price Investment Management, Inc.(19.0%)
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-Vestal Point Capital, LP(8.9%),Ryan Wilder(8.9%)
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 4:持股變動聲明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股變動聲明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股變動聲明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股變動聲明-股東 Versant Venture Capital VI, L.P.
Black Diamond Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Versant Ventures VI GP, L.P.(7.7%),Versant Ventures VI GP-GP, LLC(7.7%)等
Black Diamond Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-T. Rowe Price Investment Management, Inc.(18.9%)
Black Diamond Therapeutics | 4:持股變動聲明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股變動聲明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股變動聲明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股變動聲明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股變動聲明-董事 Kulkarni Samarth
Black Diamond Therapeutics | 4:持股變動聲明-董事 Menzel Garry E
Black Diamond Therapeutics | 4:持股變動聲明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股變動聲明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股變動聲明-董事 Dhingra Kapil
Black Diamond Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Ali Behbahani(8.1%),New Enterprise Associates 16, L.P.(7.9%)等
暫無數據
暫無數據